Stingray Therapeutics Overview
Stingray is developing potent and selective small molecule inhibitors of ENPP1. ENPP1 is the direct negative regulator of the STING pathway which is essential for innate immune response. We have generated promising preliminary data and expect to file our IND in March 2023.
Address: Salt Lake City, UT